Intrinsiqq
Exelixis Inc. logo

Exelixis Inc. Financials

EXEL

⊜ Compare

All currency values in $ millions unless otherwise noted

Scroll

Showing 6 of 20 available years
Income Statement
TTM
JAN 2026
JAN 2025
DEC 2023
DEC 2022
DEC 2021
Revenues
Revenue$2,497$2,320$2,169$1,830$1,611$1,435
Cost of Revenue$93$84$76$73$58$53
Gross Profit$2,404$2,236$2,092$1,758$1,553$1,382
General & Administrative$565$519$492$543$460$402
Research & Development$835$825$910$1,044$892$694
Total Operating Expenses$1,493$1,448$1,564$1,659$1,410$1,148
Operating Income$1,003$872$605$171$201$287
Other Non-Operating Income (Expense)$0-$0-$0$0-$0-$0
Income Tax Expense$181$159$160$50$52$63
Net Income
Net Income$885$783$521$208$182$231
Per Share Data
Revenue Per Share$9.76$8.23$7.32$5.69$4.96$4.45
EPS (Basic)$3.45$2.88$1.80$0.65$0.57$0.73
EPS (Diluted)$3.35$2.78$1.76$0.65$0.56$0.72
Weighted Avg Shares (Basic)246.8M271.6M290.0M318.2M321.5M314.9M
Weighted Avg Shares (Diluted)255.8M281.9M296.1M321.5M324.6M322.4M
Shares Outstanding255.8M281.9M296.1M321.5M324.6M322.4M

Exelixis (EXEL) financials: revenue, profit and margins

Exelixis (EXEL) generated about $2.5 billion in revenue and $885 million in net income (a 35.5% net margin) over the trailing twelve months, growing at roughly 18.6% a year. Figures are from SEC filings; this is analysis, not investment advice.

Frequently asked

What is Exelixis's (EXEL) revenue?+

Exelixis generated about $2.5 billion in revenue over the trailing twelve months. Revenue has grown at roughly 18.6% a year over the past five years. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.

Is Exelixis profitable?+

Yes, Exelixis reported about $885 million in net income over the trailing twelve months, a net profit margin of roughly 35.5%. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

What are Exelixis's profit margins?+

Exelixis runs a gross margin of about 96.3%, an operating margin of about 40.2%, a net margin of about 35.5%. Margins show how much of each sales dollar a company keeps at each stage. Stable or rising margins usually signal pricing power and cost discipline; falling margins are worth investigating. See the multi-year trend on this tab.

How fast is Exelixis growing?+

Exelixis's revenue has compounded at roughly 18.6% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside EXEL's margins and free cash flow. This is analysis from SEC filings, not investment advice.

How the market compares: How many US companies are profitable

SourceFinancial statements computed from the 10-Q filed 19 Oct 2026, covering the period ending 2 Oct 2026, as reported to the SEC. Data last refreshed 30 Oct 2026. How this is calculated.

Fiscal year ends Jan.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with EXEL

CompareIntrinsic value
INCYIncyte Corporation
$122.83+4.46%43
JAZZJazz Pharmaceuticals plc
$234.66+2.14%58
HALOHalozyme Therapeutics Inc.
$130.34+1.34%66
BMRNBiomarin Pharmaceutical Inc.
$57.13+2.64%47
NBIXNeurocrine Biosciences Inc.
$167.21+1.43%85

Held by ETFs

EXEL is in 213 US ETFs. The largest of them, with EXEL's weight in each:

Spot a number that looks wrong? Check it in EXEL's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing EXEL

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.